The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Psoriasis Market Evolve From 2026 To 2030?
The psoriasis market size has shown substantial growth in recent years. It is anticipated to increase from $28.93 billion in 2025 to $31.41 billion in 2026, representing a compound annual growth rate (CAGR) of 8.5%. This historical growth can be linked to the rising prevalence of autoimmune skin disorders, the widespread application of corticosteroids, improvements in dermatology diagnosis rates, the expansion of hospital dermatology units, and a greater awareness of chronic skin diseases.
The psoriasis market is projected to experience substantial expansion in the coming years, anticipated to reach a valuation of $44.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This remarkable growth during the forecast period is primarily driven by an increase in biologic drug approvals, heightened patient awareness, a rise in the diagnosis of severe psoriasis cases, the proliferation of specialty clinics, and increased healthcare expenditure dedicated to dermatology. Concurrently, major trends emerging in this period include the growing adoption of biologic therapies for psoriasis, the development of more comprehensive long-term disease management strategies, a rising demand for injectable psoriasis treatments, the expansion of both hospital and specialized dermatology care services, and an intensified focus on moderate-to-severe forms of psoriasis.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2414&type=smp
What Major Drivers Are Influencing Demand In The Psoriasis Market?
The increasing prevalence of individuals with psoriasis is projected to stimulate the expansion of the psoriasis market in the coming years. Psoriasis is a persistent autoimmune skin condition characterized by the rapid accumulation of skin cells, leading to inflammation, scaling, and discomfort, frequently necessitating ongoing medical intervention and monitoring. The growth in psoriasis patients is attributed to an overactive immune system mistakenly attacking healthy skin cells, often initiated or worsened by environmental triggers such as infections, stress, or skin trauma. This rising occurrence of psoriasis bolsters the psoriasis market by generating higher demand for biologics, topical agents, immunomodulators, and phototherapy treatments designed to reduce flare-ups, alleviate symptoms, and improve patient quality of life. For instance, in 2025, the Global Psoriasis Atlas, a UK-based research organization focused on psoriasis, estimates that 43 million people have psoriasis based on diagnoses by physicians and dermatologists, while approximately 102 million people report having psoriasis through self-reported cases. Therefore, the increase in the prevalence of psoriasis patients is a significant force driving the growth of the psoriasis market.
Which Segment Areas Are Covered In The Psoriasis Market Analysis?
The psoriasis market covered in this report is segmented –
1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor
2) By Drug Types: Small molecules, Biologics
3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis
4) By Route Of Administration: Oral, Topical, Injectable
5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce
Subsegments:
1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab)
2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone)
3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)
What Key Developments And Trends Are Impacting The Psoriasis Market?
Companies in the psoriasis market are emphasizing innovations in products and their formulations, such as auto-injector delivery systems for biosimilars. This focus aims to enhance patient adherence, convenience, and treatment outcomes, without compromising the efficacy and safety of reference biologics. These advancements allow for self-administration, reduce discomfort from injections, and promote wider acceptance of biosimilar therapies in Europe and other markets. For example, in May 2025, Sandoz, a Switzerland-based biopharmaceutical company, introduced the Pyzchiva autoinjector, which is the first commercially available autoinjector for ustekinumab biosimilars in Europe. The Pyzchiva autoinjector is crafted to offer simple, accurate, and patient-friendly administration of biosimilar ustekinumab, thereby supporting better adherence for the ongoing management of chronic psoriasis. This product launch highlights a developing market trend towards improving patient-centric delivery options for biologics and biosimilars, increasing both accessibility and convenience for individuals living with psoriasis.
Which Global Companies Are Actively Competing In The Psoriasis Market?
Major companies operating in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy’s Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy
Read the full psoriasis market report here:
https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report
Which Region Shows The Strongest Potential For Future Growth In The Psoriasis Market?
North America was the largest region in the psoriasis market in 2025. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Psoriasis Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2414&type=smp
Browse Through More Reports Similar to the Global Psoriasis Market 2026, By The Business Research Company
Psoriasis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report
Dermatitis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Dermatology Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model